These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 22624467)

  • 21. Co-administration of certain DNA vaccine combinations expressing different H5N1 influenza virus antigens can be beneficial or detrimental to immune protection.
    Patel A; Gray M; Li Y; Kobasa D; Yao X; Kobinger GP
    Vaccine; 2012 Jan; 30(3):626-36. PubMed ID: 22119588
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Looming flu pandemic has experts crying fowl.
    Clayton J
    Nat Med; 2003 Apr; 9(4):375. PubMed ID: 12669040
    [No Abstract]   [Full Text] [Related]  

  • 23. Plant-produced recombinant influenza vaccine based on virus-like HBc particles carrying an extracellular domain of M2 protein.
    Ravin NV; Kotlyarov RY; Mardanova ES; Kuprianov VV; Migunov AI; Stepanova LA; Tsybalova LM; Kiselev OI; Skryabin KG
    Biochemistry (Mosc); 2012 Jan; 77(1):33-40. PubMed ID: 22339631
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Immunogenicity of recombinant proteins including ectodomain of M2 influenza virus A].
    Stepanova LA; Kovaleva AA; Potapchuk MV; Korotkov AV; Kupriianov VV; Blokhina EA; Kotliarov RIu; Tsybalova LM
    Vopr Virusol; 2013; 58(3):21-5. PubMed ID: 24006628
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prospects for broadly protective influenza vaccines.
    Treanor JJ
    Vaccine; 2015 Nov; 33 Suppl 4():D39-45. PubMed ID: 26338145
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Fabrication of influenza virus-like particles using M2 fusion proteins for imaging single viruses and designing vaccines.
    Wei HJ; Chang W; Lin SC; Liu WC; Chang DK; Chong P; Wu SC
    Vaccine; 2011 Sep; 29(41):7163-72. PubMed ID: 21651946
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Universal type/subtype-specific antibodies for quantitative analyses of neuraminidase in trivalent influenza vaccines.
    Xu K; Li C; Gravel C; Jiang Z; Jaentschke B; Van Domselaar G; Li X; Wang J
    Sci Rep; 2018 Jan; 8(1):1067. PubMed ID: 29348625
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Conserved epitopes of influenza A virus inducing protective immunity and their prospects for universal vaccine development.
    Staneková Z; Varečková E
    Virol J; 2010 Nov; 7():351. PubMed ID: 21118546
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Recognition of the PB1, neuraminidase, and matrix proteins of influenza virus A/NT/60/68 by cytotoxic T lymphocytes.
    Reay PA; Jones IM; Gotch FM; McMichael AJ; Brownlee GG
    Virology; 1989 Jun; 170(2):477-85. PubMed ID: 2658303
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Infectious diseases. WHO ramps up bird flu vaccine efforts.
    Normile D
    Science; 2004 Jan; 303(5658):609. PubMed ID: 14752135
    [No Abstract]   [Full Text] [Related]  

  • 31. Enhanced Influenza VLP vaccines comprising matrix-2 ectodomain and nucleoprotein epitopes protects mice from lethal challenge.
    Gao X; Wang W; Li Y; Zhang S; Duan Y; Xing L; Zhao Z; Zhang P; Li Z; Li R; Wang X; Yang P
    Antiviral Res; 2013 Apr; 98(1):4-11. PubMed ID: 23416215
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Universal M2 ectodomain-based influenza A vaccines: preclinical and clinical developments.
    Schotsaert M; De Filette M; Fiers W; Saelens X
    Expert Rev Vaccines; 2009 Apr; 8(4):499-508. PubMed ID: 19348565
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Examination of influenza specific T cell responses after influenza virus challenge in individuals vaccinated with MVA-NP+M1 vaccine.
    Powell TJ; Peng Y; Berthoud TK; Blais ME; Lillie PJ; Hill AV; Rowland-Jones SL; McMichael AJ; Gilbert SC; Dong T
    PLoS One; 2013; 8(5):e62778. PubMed ID: 23658773
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A lipopeptide based on the M2 and HA proteins of influenza A viruses induces protective antibody.
    Pejoski D; Zeng W; Rockman S; Brown LE; Jackson DC
    Immunol Cell Biol; 2010 Jul; 88(5):605-11. PubMed ID: 20177411
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Preclinical efficacy of a prototype DNA vaccine: enhanced protection against antigenic drift in influenza virus.
    Donnelly JJ; Friedman A; Martinez D; Montgomery DL; Shiver JW; Motzel SL; Ulmer JB; Liu MA
    Nat Med; 1995 Jun; 1(6):583-7. PubMed ID: 7585127
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of the ability of viral protein-expressing plasmid DNAs to protect against influenza.
    Chen Z; Sahashi Y; Matsuo K; Asanuma H; Takahashi H; Iwasaki T; Suzuki Y; Aizawa C; Kurata T; Tamura S
    Vaccine; 1998 Oct; 16(16):1544-9. PubMed ID: 9711802
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pandemic H1N1 influenza virus-like particles are immunogenic and provide protective immunity to pigs.
    Pyo HM; Masic A; Woldeab N; Embury-Hyatt C; Lin L; Shin YK; Song JY; Babiuk S; Zhou Y
    Vaccine; 2012 Feb; 30(7):1297-304. PubMed ID: 22207090
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Engineered Nanoparticle Applications for Recombinant Influenza Vaccines.
    Sia ZR; Miller MS; Lovell JF
    Mol Pharm; 2021 Feb; 18(2):576-592. PubMed ID: 32787280
    [TBL] [Abstract][Full Text] [Related]  

  • 39. M2e-based universal influenza vaccines: a historical overview and new approaches to development.
    Mezhenskaya D; Isakova-Sivak I; Rudenko L
    J Biomed Sci; 2019 Oct; 26(1):76. PubMed ID: 31629405
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cell-based protein vaccines for influenza.
    Cox MM
    Curr Opin Mol Ther; 2005 Feb; 7(1):24-9. PubMed ID: 15732526
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.